Hanna Huopio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hanna Huopio has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Frances Ashcroft
Department of Pediatrics, Kuopio University Hospital, Kuopio, Finland2University Laboratory of Physiology, University of Oxford, Oxford, United Kingdom3Department of Paediatrics, Tampere University Hospital, Tampere, Finland4University Hospital St. Luc, Bruxelles, Belgium5Department of Medicine, Kuopio University Hospital, Kuopio, Finland6Finnish Genome Center, and7Transplantation Laboratory, Haartman Institute, and the Hospital for Children and Adolescents, University of Helsinki, Finland
1 shared publication- Frank Reimann
Institute of Metabolic Science-Metabolic Research Laboratories & MRC-Metabolic Diseases Unit, University of Cambridge, Cambridge, UK
1 shared publication Hanna-Liisa Lenko
Department of Pediatrics, Kuopio University Hospital, Kuopio, Finland2University Laboratory of Physiology, University of Oxford, Oxford, United Kingdom3Department of Paediatrics, Tampere University Hospital, Tampere, Finland4University Hospital St. Luc, Bruxelles, Belgium5Department of Medicine, Kuopio University Hospital, Kuopio, Finland6Finnish Genome Center, and7Transplantation Laboratory, Haartman Institute, and the Hospital for Children and Adolescents, University of Helsinki, Finland
1 shared publicationIlkka Vauhkonen
Department of Pediatrics, Kuopio University Hospital, Kuopio, Finland2University Laboratory of Physiology, University of Oxford, Oxford, United Kingdom3Department of Paediatrics, Tampere University Hospital, Tampere, Finland4University Hospital St. Luc, Bruxelles, Belgium5Department of Medicine, Kuopio University Hospital, Kuopio, Finland6Finnish Genome Center, and7Transplantation Laboratory, Haartman Institute, and the Hospital for Children and Adolescents, University of Helsinki, Finland
1 shared publicationJ. Jääskeläinen
1 shared publicationJ. Komulainen
1 shared publication
Latest Publications
- 1 October 2002
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 87 (10) , 4502-4507
Acute Insulin Response Tests for the Differential Diagnosis of Congenital Hyperinsulinism
Mutations in genes encoding the two subunits of the beta-cell ATP-sensitive potassium channel (K(ATP)) channel (SUR1 and Kir6.2) are the major cause of congenital hyperinsulinism (CHI). In this study, the K(ATP) channel genes were screened in a population-based study that included all verified Finnish CHI patients (n = 43) in a 27-yr period. Seven different mutations were identified, which accounted for 60% of all cases. The functional consequences of the major missense mutations were studied in vivo by determining acute (1-3 min) plasma insulin and C-peptide responses to calcium (n = 18), glucose (n = 12), and tolbutamide (n = 11) in those CHI patients who were able to take part in these studies. C-peptide and insulin responses to calcium were significantly higher in the patients with SUR1-E1506K mutation, compared with patients without K(ATP) channel mutations. The patients with SUR1-V187D mutation showed a reduced response to tolbutamide but unexpectedly did not show any response to calcium stimulation. A compound heterozygous patient with Kir6.2-(-54)/K67N mutations responded to calcium but also to tolbutamide. In conclusion, our results show that a positive response in the calcium test is indicative of a K(ATP) channel mutation, but all mutations cannot be identified with this method. The insulin response to tolbutamide in patients with SUR1 mutations is impaired to different extents, depending on the genotype. The combination of calcium and tolbutamide tests is a useful tool for the detection of CHI patients with K(ATP) channel dysfunction. Our results, however, also demonstrate the complexity of these responses and the difficulties in their interpretation.
- 1 October 2002
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 87 (10) , 4502-4507
Acute Insulin Response Tests for the Differential Diagnosis of Congenital Hyperinsulinism
Mutations in genes encoding the two subunits of the beta-cell ATP-sensitive potassium channel (K(ATP)) channel (SUR1 and Kir6.2) are the major cause of congenital hyperinsulinism (CHI). In this study, the K(ATP) channel genes were screened in a population-based study that included all verified Finnish CHI patients (n = 43) in a 27-yr period. Seven different mutations were identified, which accounted for 60% of all cases. The functional consequences of the major missense mutations were studied in vivo by determining acute (1-3 min) plasma insulin and C-peptide responses to calcium (n = 18), glucose (n = 12), and tolbutamide (n = 11) in those CHI patients who were able to take part in these studies. C-peptide and insulin responses to calcium were significantly higher in the patients with SUR1-E1506K mutation, compared with patients without K(ATP) channel mutations. The patients with SUR1-V187D mutation showed a reduced response to tolbutamide but unexpectedly did not show any response to calcium stimulation. A compound heterozygous patient with Kir6.2-(-54)/K67N mutations responded to calcium but also to tolbutamide. In conclusion, our results show that a positive response in the calcium test is indicative of a K(ATP) channel mutation, but all mutations cannot be identified with this method. The insulin response to tolbutamide in patients with SUR1 mutations is impaired to different extents, depending on the genotype. The combination of calcium and tolbutamide tests is a useful tool for the detection of CHI patients with K(ATP) channel dysfunction. Our results, however, also demonstrate the complexity of these responses and the difficulties in their interpretation.
- Open Access
- 1 October 2000
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 106 (7) , 897-906
Dominantly inherited hyperinsulinism caused by a mutation in the sulfonylurea receptor type 1
ATP-sensitive potassium channels play a major role in linking metabolic signals to the exocytosis of insulin in the pancreatic β cell. These channels consist of two types of protein subunit: the sulfonylurea receptor SUR1 and the inward rectifying potassium channel Kir6.2. Mutations in the genes encoding these proteins are the most common cause of congenital hyperinsulinism (CHI). Since 1973, we have followed up 38 pediatric CHI patients in Finland. We reported previously that a loss-of-function mutation in SUR1 (V187D) is responsible for CHI of the most severe cases. We have now identified a missense mutation, E1506K, within the second nucleotide binding fold of SUR1, found heterozygous in seven related patients with CHI and in their mothers. All patients have a mild form of CHI that usually can be managed by long-term diazoxide treatment. This clinical finding is in agreement with the results of heterologous coexpression studies of recombinant Kir6.2 and SUR1 carrying the E1506K mutation. Mutant KATP channels were insensitive to metabolic inhibition, but a partial response to diazoxide was retained. Five of the six mothers, two of whom suffered from hypoglycemia in infancy, have developed gestational or permanent diabetes. Linkage and haplotype analysis supported a dominant pattern of inheritance in a large pedigree. In conclusion, we describe the first dominantly inherited SUR1 mutation that causes CHI in early life and predisposes to later insulin deficiency.
- 1 October 2000
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 106 (7) , 897-906
Open AccessDominantly inherited hyperinsulinism caused by a mutation in the sulfonylurea receptor type 1
ATP-sensitive potassium channels play a major role in linking metabolic signals to the exocytosis of insulin in the pancreatic β cell. These channels consist of two types of protein subunit: the sulfonylurea receptor SUR1 and the inward rectifying potassium channel Kir6.2. Mutations in the genes encoding these proteins are the most common cause of congenital hyperinsulinism (CHI). Since 1973, we have followed up 38 pediatric CHI patients in Finland. We reported previously that a loss-of-function mutation in SUR1 (V187D) is responsible for CHI of the most severe cases. We have now identified a missense mutation, E1506K, within the second nucleotide binding fold of SUR1, found heterozygous in seven related patients with CHI and in their mothers. All patients have a mild form of CHI that usually can be managed by long-term diazoxide treatment. This clinical finding is in agreement with the results of heterologous coexpression studies of recombinant Kir6.2 and SUR1 carrying the E1506K mutation. Mutant KATP channels were insensitive to metabolic inhibition, but a partial response to diazoxide was retained. Five of the six mothers, two of whom suffered from hypoglycemia in infancy, have developed gestational or permanent diabetes. Linkage and haplotype analysis supported a dominant pattern of inheritance in a large pedigree. In conclusion, we describe the first dominantly inherited SUR1 mutation that causes CHI in early life and predisposes to later insulin deficiency.